Northern Trust
ADAP

Northern Trust’s Adaptimmune Therapeutics ADAP Stock Holding History

Northern Trust’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-48,584
Closed -$6.32K – 4450
2025
Q3 		$6.32K Sell
48,584
-2,749
-5% -$377 ﹤0.01% 4415
2025
Q2 		$12.3K Hold
51,333
– – ﹤0.01% 4368
2025
Q1 		$10.1K Hold
51,333
– – ﹤0.01% 4386
2024
Q4 		$27.7K Hold
51,333
– – ﹤0.01% 4345
2024
Q3 		$48.8K Sell
51,333
-528
-1% -$599 ﹤0.01% 4216
2024
Q2 		$50.6K Sell
51,861
-5,639
-10% -$6.19K ﹤0.01% 4213
2024
Q1 		$90.8K Buy
57,500
+77
+0.1% +$93 ﹤0.01% 4103
2023
Q4 		$45.5K Hold
57,423
– – ﹤0.01% 4251
2023
Q3 		$44.8K Sell
57,423
-1,346
-2% -$1.13K ﹤0.01% 4194
2023
Q2 		$54.4K Buy
+58,769
New +$70.1K ﹤0.01% 4203
2021
Q1 		– Sell
-50,000
Closed -$270K – 4473
2020
Q4 		$270K Buy
+50,000
New +$272K ﹤0.01% 3895

Other funds holding ADAP

JAIC
Josh Arnold Investment Consultant Edina, Minnesota $117M AUM 26.5% 1-Year Est. Return
EF
Empirical Finance Havertown, Pennsylvania $2.13B AUM 29.56% 1-Year Est. Return
RG
Rathbones Group Liverpool, United Kingdom $25B AUM 18.87% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $3.23B AUM 62.07% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $280B AUM 33.63% 1-Year Est. Return